Bone and Connective Tissue Cancer

RECALL: Hospira Injectable Products Recall

Hospira and the FDA are notifying healthcare professionals of a nationwide recall of 19 lots of injectable carboplatin, cytarabine, paclitaxel, and methotrexate due to visible particles embedded in the glass at the neck of the vial.

FDA Issues Complete Response Letter to NDA for Ridaforolimus

Merck announced that the FDA has issued a complete response letter regarding its New Drug Application (NDA) for ridaforolimus, an investigational medicine under development for maintenance therapy in patients with metastatic soft tissue or bone sarcoma who have stable disease or better after four or more cycles of chemotherapy.

Cancer Prevention Guidelines Updated

The American Cancer Society (ACS) Nutrition and Physical Activity Guidelines were recently updated and published in the January/February issue of CA: A Cancer Journal for Clinicians.

ROR2 ID’d As Novel Biomarker of Soft-Tissue Sarcomas

ROR2 gene mutations are expressed in a subset of soft-tissue sarcomas, including leiomyosarcoma (LMS), gastrointestinal stromal tumors (GIST), and desmoid-type fibromatosis (DTF), and expression may be indicative of poor prognosis.